Невролупус

Main Article Content

Smiljana Bundovska
Dafina Kuzmanovska

Апстракт

СиÑтемÑки Ð»ÑƒÐ¿ÑƒÑ ÐµÑ€Ð¸Ñ‚ÐµÐ¼Ð°Ñ‚Ð¾Ð·ÑƒÑ (СЛЕ) не е невообичаена ÑоÑтојба. Повеќето невролози Ñе ÑвеÑни дека Ñ‚aa може да предизвика широк Ñпектар на невролошки компликации, и СЛЕ речиÑи Ñекогаш Ñе појавува на лиÑта на "диференцијална дијагноза" во Ñлучаи на клиничка неÑигурноÑÑ‚. Сепак, точната природа на манифеÑтациите на СЛЕ во централниот и периферниот нервен ÑиÑтем е можеби помалку разбрана, и заблудите за феноменот и третманот Ñе чеÑти. Ќе бидат разгледани некои од главните примарни невролошки компликации на СЛЕ - 'невролупуÑ' - земјќи во обзир дека второÑтепените проблеми во врÑка Ñо други поÑледици од СЛЕ (на пример, хипертензивна болеÑÑ‚ на ЦÐС појава како резултат на бубрежен лупуÑ) не Ñе ниту помалку Ñериозни ниту пак може полеÑно да Ñе лекуваат.

Downloads

Download data is not yet available.

Article Details

Како да се цитира
Bundovska, S., & Kuzmanovska, D. (2015). Невролупус. Македонско медицинско електронско списание, 2015, 1–8. https://doi.org/10.3889/mmej.2015.50013
Секција
Ревиски труд

Референци

Jimйnez S, Cervera R, Font J, et al. The epidemiology of systemic lupus erythematosus. Clin Rev Allergy Immunol. 2003;25:3–12.

Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40:1725.

Hanly JG, McCurdy G, Fougere L, et al. Neuropsychiatric events in systemic lupus erythematosus: attribution and clinical significance. Rheumatol. 2004;31:2156–62.

Hanly JG, Fisk JD, McCurdy G, et al. Neuropsychiatric syndromes in patients with systemic lupus erythematosus and rheumatoid arthritis. J Rheumatol. 2005;32:1459–6.

Hanly JG, Su L, Farewell V, et al. Prospective study of neuropsychiatric events in systemic lupus erythematosus. J Rheumatol. 2009;36:1449–59.

Ainiala H, Loukkola J, Peltola J, et al. The prevalence of neuropsychiatric syndromes in systemic lupus erythematosus. Neurology. 2001;57:496–500.

Scolding NJ, Joseph FG. The neuropathology and pathogenesis of systemic lupus erythematosus. Neuropathol Appl Neurobiol. 2002;28:173–89.

Johnson RT, Richardson EP. The neurological manifestations of systemic lupus erythematosus. Medicine (Baltimore). 1968;47:337–69.

Ellis SG, Verity MA. Central nervous system involvement in systemic lupus erythematosus: a review of neuropathologic findings in 57 cases, 1955–1977. Semin Arthritis Rheum. 1979;8:212–21.

Devinsky O, Petito CK, Alonso DR. Clinical and neuropathological findings in systemic lupus erythematosus: the role of vasculitis, heart emboli, and thrombotic thrombocytopenic purpura. Ann Neurol. 1988;23:380–4.

Hanly JG, Walsh NM, Sangalang V. Brain pathology in systemic lupus erythematosus. J Rheumatol. 1992;19:732–41.

Karassa FB, Afeltra A, Ambrozic A, et al. Accuracy of anti-ribosomal P protein antibody testing for the diagnosis of neuropsychiatric systemic lupus erythematosus: an international meta-analysis. Arthritis Rheum. 2006;54:312–24.

Asherson RA, Cervera R, Merrill JT, et al. Antiphospholipid antibodies and the antiphospholipid syndrome: clinical significance and treatment. Semin Thromb Hemost. 2008;34:256–66.

The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum. 1999;42:599–608.

Mitsikostas DD, Sfikakis PP, Goadsby PJ. A meta-analysis for headache in systemic lupus erythematosus: the evidence and the myth. Brain. 2004;127:1200–9.

Cimaz R, Meroni PL, Shoenfeld Y. Epilepsy as part of systemic lupus erythematosus and systemic antiphospholipid syndrome (Hughes syndrome). Lupus. 2006;15:191–7.

Joseph FG, Lammie GA, Scolding NJ. CNS lupus: a study of 41 patients. Neurology. 2007;69:644–54.

Devreese K, Hoylaerts MF. Laboratory diagnosis of the antiphospholipid syndrome: a plethora of obstacles to overcome. Eur J Haematol. 2009;83:1–16.

Wong RC, Favaloro EJ. Clinical features, diagnosis, and management of the antiphospholipid syndrome. Semin Thromb Hemost. 2008;34:295–304.

Bayraktar UD, Erkan D, Bucciarelli S, et al; Catastrophic Antiphospholipid Syndrome Project Group. The clinical spectrum of catastrophic antiphospholipid syndrome in the absence and presence of lupus. J Rheumatol. 2007;34:346–52.

Scolding NJ, ed. Systemic inflammatory diseases and the nervous system. In: Contemporary treatments in neurology. Oxford: Butterworth Heinemann, 2001:187–215.

Stojanovich L, Zandman-Goddard G, Pavlovich S, et al. Psychiatric manifestations in systemic lupus erythematosus. Autoimmun Rev. 2007;6:421–6.

Pego-Reigosa JM, Isenberg DA. Psychosis due to systemic lupus erythematosus: characteristics and long-term outcome of this rare manifestation of the disease. Rheumatology (Oxford). 2008;47:1498–502.

Denburg SD, Carbotte RM, Denburg JA. Cognition and mood in systemic lupus erythematosus. Evaluation and pathogenesis. Ann N Y Acad Sci. 1997;823:44–59.

Kovacs B, Lafferty TL, Brent LH, et al. Transverse myelopathy in systemic lupus erythematosus: an analysis of 14 cases and review of the literature. Ann Rheum Dis. 2000;59:120–4.

Espinosa G, Mendizábal A, Mí­nguez S, Ramo-Tello C, Capellades J, Olivé A, Cervera R. Transverse myelitis affecting more than 4 spinal segments associated with systemic lupus erythematosus: clinical, immunological, and radiological characteristics of 22 patients. Semin Arthritis Rheum. 2010;39(4):246-56.

Pittock SJ, Lennon VA, de Seze J, et al. Neuromyelitis optica and non organ-specific autoimmunity. Arch Neurol. 2008;65:78–83.

Fulford KW, Catterall RD, Delhanty JJ, et al. A collagen disorder of the nervous system presenting as multiple sclerosis. Brain. 1972;95:373–86.

Rosenbaum R. Neuromuscular complications of connective tissue diseases. Muscle Nerve. 2001;24:154–69.

Vina ER, Fang AJ, Wallace DJ, et al. Chronic inflammatory demyelinating polyneuropathy in patients with systemic lupus erythematosus: prognosis and outcome. Semin Arthritis Rheum. 2005;35:175–84.

Bhinder S, Majithia V, Harisdangkul V. Myasthenia gravis and systemic lupus erythematosus: truly associated or coincidental"”two case reports and review of the literature. Clin Rheumatol. 2006;25:555–6.

Cuchacovich R, Gedalia A. Pathophysiology and clinical spectrum of infections in systemic lupus erythematosus. Rheum Dis Clin North Am. 2009;35:75–93.

Karassa FB, Ioannidis JP, Touloumi G, et al. Risk factors for central nervous system involvement in systemic lupus erythematosus. QJM. 2000;93:169–74.

Creamer P, Kirwan J. Seronegative systemic lupus erythematosus. Br J Rheumatol. 1992;31:619–22.

Craig WY, Ledue TB, Johnson AM, et al. The distribution of antinuclear antibody titers in "normal" children and adults. J Rheumatol. 1999;26:914–19.

Appenzeller S, Pike GB, Clarke AE. Magnetic resonance imaging in the evaluation of central nervous system manifestations in systemic lupus erythematosus. Clin Rev Allergy Immunol. 2008;34:361–6.

Graham JW, Jan W. MRI and the brain in systemic lupus erythematosus. Lupus. 2003;12:891–6.

Peterson PL, Axford JS, Isenberg D. Imaging in CNS lupus. Best Pract Res Clin Rheumatol. 2005;19:727–39.

Castellino G, Govoni M, Giacuzzo S, et al. Optimizing clinical monitoring of central nervous system involvement in SLE. Autoimmun Rev. 2008;7:297–304.

Guttman M, Lang AE, Garnett ES, et al. Regional cerebral glucose metabolism in SLE chorea: further evidence that striatal hypometabolism is not a correlate of chorea. Mov Disord. 1987;2:201–10.

Crowther MA, Ginsberg JS, Julian J, et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med. 2003;349:1133–8.

Finazzi G, Marchioli R, Brancaccio V, et al. A randomized clinical trial of highintensity warfarin vs. Conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). J Thromb Haemost. 2005;3:848–53.

Lim W, Crowther MA, Eikelboom JW. Management of antiphospholipid antibody syndrome: a systematic review. JAMA. 2006;295:1050–7.

Trevisani VF, Castro AA, Neves Neto JF, et al. Cyclophosphamide versus methylprednisolone for treating neuropsychiatric involvement in systemic lupus erythematosus. Cochrane Database Syst Rev. 2006;19:CD002265.

Barile-Fabris L, Ariza-Andraca R, Olguнn-Ortega L, et al. Controlled clinical trial of IV cyclophosphamide versus IV methylprednisolone in severe neurological manifestations in systemic lupus erythematosus. Ann Rheum Dis. 2005;64:620–5.